DIRS.INFO The most relevant business & tech news

☆ The questions eating disorder experts have about weight loss medications
▼ + stars: | 2024-02-26 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +8 min

CNN —There is still much researchers don’t know about popular weight loss medications — and those lack of studies could have consequences for eating disorders, according to experts. As the medication become more available, experts said they worry about the impact of these weight loss products on eating disorders. “The eating disorder field is hard because we’re just ignored.”Can these drugs treat binge eating disorder? Binge eating disorder is the most common eating disorder. “A lot of eating disorders do begin with restricted food intake and weight loss,” she said.

Persons: ”, Aaron Keshen, Jennifer Gaudiani, Susan McElroy, Linda, Harry Fath, McElroy, “, ” McElroy, ” Keshen, it’s, Keshen, Gaudiani, ” Gaudiani, “ it’s, ‘, haven’t Organizations: CNN, Nova, Disorder, National Association, Disorders, Gaudiani Clinic, Lindner, of HOPE, University of Cincinnati College of Medicine, International Locations: Nova Scotia, Dalhousie University’s, Halifax , Nova Scotia, United States, Denver, Minnesota

☆ Using Opera to Shine a Light on Wrongful Imprisonment
▼ + stars: | 2024-02-15 | by ( Javier C. Hernández | ) www.nytimes.com time to read: +1 min

Near the end of “Blind Injustice,” an opera about six people who were wrongfully convicted of crimes and later freed, the exonerees reflect on the time they have spent behind bars. “What makes a person strong enough to endure injustice?” they sing. The work, which was commissioned by Cincinnati Opera and premiered there in 2019, explores the effects of wrongful convictions on the prisoners and their families, and the help to overturn their convictions that they received from the Ohio Innocence Project, a nonprofit organization at the University of Cincinnati College of Law. One man who was sent to death row describes spending 39 years in prison after being wrongfully convicted of murder. A bus driver falsely accused of sexual abuse describes the pain of being separated from her four children.

Persons: ”, Scott Davenport Richards, David Cote Organizations: Montclair State University, Cincinnati Opera, Ohio Innocence, University of Cincinnati College of Law Locations: Ohio

Signage for Eisai Co. at the company's headquarters in Tokyo, Japan, on Friday, Feb. 3, 2023. Bloomberg | Bloomberg | Getty ImagesShares of Japanese pharmaceutical giant Eisai sank Friday after the company's Alzheimer's drug was formally approved by U.S. regulators overnight, prompting questions over investor sentiment surrounding the move. Eisai shares closed 4.67% lower after paring some of its earlier losses. Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval. "The odds for brain swelling and hemorrhage are far higher than any actual improvement," Espay, who launched a petition in June calling for the Alzheimer's treatment to not get full approval, told NBC News.

Persons: Biogen, Dr, Alberto Espay, Espay, Ivan Cheung, CNBC's, Cheung Organizations: Bloomberg, Getty, U.S, . Food, Medicare, University of Cincinnati College of, NBC News, Eisai U.S Locations: Tokyo, Japan, Eisai

A newly approved Alzheimer's drug will be available to patients in the coming days, according to its maker, the Japanese pharmaceutical company Eisai. While Leqembi offers hope to patients and their families, experts say that there are still some key unanswered questions about the drug, including about its safety and effectiveness. Besides questions about who will benefit the most, there are also questions about how long the drug will benefit patients. About 17% of the Leqembi group experienced brain bleeds, compared with 9% in the placebo group. The reports of brain bleeding and brain swelling "may only be the tip of the iceberg," he said.

A newly approved drug intended to slow the progression of Alzheimer’s disease offers patients hope, but it will come with a steep price tag: $26,500 a year. That drug initially cost $56,000 per year before Biogen slashed the price in half, to $28,000 annually. Dr. David Rind, the institute's chief medical officer, said an appropriate cost for the drug is $8,500 to $20,600 a year. John Domeck, 60, of Aurora, Ohio is currently enrolled in a phase 3 clinical trial testing Leqembi. But right now, the clinical trial for Leqembi shows that the drug provides "modest efficacy at a big, big price," Caplan said.

Buffalo Bills safety Damar Hamlin triumphantly left an Ohio hospital Monday, a week after he collapsed on the field during a nationally televised game against the Cincinnati Bengals. Hamlin has been released and returned to Buffalo. Hamlin has been the target of unwavering support of football fans since his cardiac arrest in the first quarter of last week's "Monday Night Football" game at Paycor Stadium. On-field medical staff rushed to Hamlin and administered CPR before he was taken to the University of Cincinnati Medical Center where the player had been treated until his departure Monday. 1 and 2 teams meet in the conference title game, the top seed would get to host.

☆ Damar Hamlin's breathing tube removed, told teammates 'Love you boys' over FaceTime, Bills say
▼ + stars: | 2023-01-06 | by ( Antonio Planas | ) www.cnbc.com time to read: +3 min

The Cincinnati Reds show their support for Damar Hamlin outside of the Cincinnati Reds Hall of Fame on January 4, 2023, in Cincinnati, OH. "Damar Hamlin FaceTimed into our team meeting today to talk to players and coaches. It remains unclear what exactly caused Hamlin's cardiac arrest. The league acknowledged that canceling the game "creates potential competitive inequities in certain playoff scenarios" and said NFL clubs will consider a resolution at a special league meeting Friday. NFL Commissioner Roger Goodell said in Thursday's statement that it has been "a very difficult week" and that the league is focused on Hamlin's recovery.

☆ Statins lower the risk of one of the deadliest kinds of strokes, study finds
▼ + stars: | 2022-12-07 | by ( Jen Christensen | ) edition.cnn.com time to read: +5 min

CNN —Doctors know that drugs called statins lower a person’s risk of a stroke due to a blood clot. But a new study shows that the inexpensive medications can also decrease the risk of a first stroke as a result of an intracerebral hemorrhage, the deadliest kind. People in the study who used statins for any period of time had a 17% lower risk of a stroke in the lobe areas of the brain and a 16% lower risk of a stroke in the non-lobe areas of the brain. When they used a statin for more than five years, they had a 33% lower risk of a bleeding stroke in the lobe areas and a 38% lower risk in the non-lobe areas. She said this study shows what biologically makes sense: Taking statins and keeping fatty deposits from building up in the arteries makes hemorrhagic strokes less likely.

The Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness. The company said that in a phase 3 clinical trial, the drug, called lecanemab, slowed cognitive decline by 27% after 18 months. The results may offer renewed hope to Alzheimer’s patients after the U.S. drugmaker Biogen’s botched rollout of its drug, Aduhelm, last year. Biogen partnered with Eisai in the commercialization of the new drug, although Eisai led its development and the phase 3 trial. Two similar drugs — from Roche and Eli Lilly — are expected to release late-stage clinical trial results over the next few months.

Search resuls for: "University of Cincinnati College of"

9 mentions found